The above conflicting results may be attributed to the difference in therapeutic intensity and the probability of the presence of residual disease; residual cancer cells of high Ki-67 LI, which survive chemoradiation at a relatively low dose, may progress and be associated with worse prognosis in a study by Matsumoto et al. [10]. Here, MKI67 is linked to cancer.